AzTrials
AzTrials

Heart FailureWeigh-HFNCT07278583

Evaluation of Heart Failure Telemonitoring Eligibility Criteria

An observational study of Heart Failure, run by University Hospital, Clermont-Ferrand at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

CARDIAUVERGNE is a heart failure telemonitoring system at Clermont-Ferrand's hospital. The aim of this study is to analyze the prognosis and evolution of patients after exclusion of telemonitoring. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Heart Failure
How many people
130 participants
Where
1 siteFrance
Study dates
5 Dec 2025to Dec 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients included in CARDIAUVERGNE telemonitoring that have been excluded as they no longer fulfill the inclusion criteria

Who may be able to join

  • adults
  • able to read and understand french
  • included in CARDIAUVERGNE telemonitoring program from 1st january 2023 to 31st december 2024 such as defined by the french health authorithy criteria (heart failure within 12 months or dyspnea at least NYHA 2 associated with NTproBNP of at least 1000pg/mL) and excluded by medical decision as no longer presenting eligibillity criteria

Who cannot join

  • Patients leaving telemonitoring for other reasons (choice, death, medical reason, relocation, inobservance)

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Lise Laclautre contact

334.73.754.963

promo_interne_drci@chu-clermontferrand.fr

France1 site, 1 recruiting

  • CHU Clermont-Ferrand

    Clermont-Ferrand

    Clément RIOCREUX, 0473752489, criocreux@chu-clermontferrand.fr

    Clément RIOCREUX

    Recruiting

Other trials in France

About this study

Official title: Evaluation of Eligibility Criteria for Heart Failure Telemonitoring : Analysis of CARDIAUVERGNE's Cohort

CARDIAUVERGNE is a heart failure telemonitoring system at Clermont-Ferrand's hospital. The aim of this study is to analyze the prognosis and evolution of patients after exclusion of telemonitoring. The patients were included from 1st January 2023 to 31st December 2024 and the monitoring was terminated for end of eligibility according to the French health authority criteria.

Read the detailed description

After an episode of heart failure, patients have been included in a telemonitoring program in order to reduce rehospitalizations for heart failure and improve follow-up. On a daily basis, the patients weigh themselves on connected scales which enables a team of dedicated nurses to follow them closely. If need be they can call the patient, ask for a blood exam and adapt their prescription. Indeed, if remote support is insufficient, patients can be hospitalized prematurely and so decrease the duration of hospital care.

The inclusion criteria correspond to either an episode of heart failure in the last 12 months or dyspnea at least New York Heart Association (NYHA) 2 with NT-proBNP over 1000pg/mL.

The follow up is renewed every 6 months. Patients are excluded from monitoring when criteria are no longer fulfilled. As these characteristics have been chosen empirically, our aim is to see if patients no longer presenting these standards have indeed a low chance of bad evolution.

Information is gathered from their medical record at inclusion, exclusion and 1 year after exclusion. A short phone call is made after 1 year of exclusion, to appreciate their evolution and gather information concerning their symptoms, treatments ...

Conditions
Heart Failure
Keywords
heart failure, telemonitoring
Medical subject headings
Heart Failure

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Composite criterion defined by the occurrence within one year following the end of remote monitoring of either cardiovascular death or heart failure worsening (hospitalization or unscheduled visit for heart failure)

    Measured: From telemonitoring exclusion up to a year after

Secondary outcomes (4)

  1. Amount of medical appointments

    General practician and cardiology consultations

    Measured: From telemonitoring exclusion up to a year after

  2. Natriuretic peptides, NTproBNP, evolution

    NTproBNP comparison at inclusion, exclusion and a year after exclusion for monitoring

    Measured: From inclusion until a year after exclusion

  3. Number of patients that could theoretically be re-included during follow up

    Measured: From telemonitoring exclusion up to a year after

  4. Determination of potential patient profiles more suitable to discontinue remote monitoring

    Measured: From inclusion up to a year after telemonitoring exclusion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Dec 2025
  2. Study start5 Dec 2025
  3. Primary completionDec 2026 (estimated)
  4. Study completionDec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
130 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07278583
Sponsor's protocol ID
RNI 2025 RIOCREUX
Acronym
Weigh-HF
Status last verified
Dec 2025
First submitted
1 Dec 2025
Last updated
30 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017 Apr;3(1):7-11. doi: 10.15420/cfr.2016:25:2.

    PubMed 28785469

  • Rapport au parlement "évaluation des expérimentations de télésurveillance du programme national étapes" Novembre 2020

  • Haute Autorité Santé. "Télésurveillance médicale du patient insuffisant cardiaque chronique," 2023.

  • Authors/Task Force Members:; McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022 Jan;24(1):4-131. doi: 10.1002/ejhf.2333.

    PubMed 35083827

Questions about this trial

What is this clinical trial studying?

An observational study of Heart Failure, run by University Hospital, Clermont-Ferrand at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 30 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Lise Laclautre (334.73.754.963, promo_interne_drci@chu-clermontferrand.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Composite criterion defined by the occurrence within one year following the end of remote monitoring of either cardiovascular death or heart failure worsening (hospitalization or unscheduled visit for heart failure) (time frame: From telemonitoring exclusion up to a year after). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07278583, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in